KBC Securities - Autolus Therapeutics ADS (AUTL) Autolus FIRST LOOK: Uneventful FY23 results, obe-cels PDUFA in r/r ALL in 4Q24

Report

KBC Securities

Jacob Mekhael

Autolus FIRST LOOK: Uneventful FY23 results, obe-cel's PDUFA in r/r ALL in 4Q24

Autolus reported uneventful FY23 results, with approx. $ 240m in cash (plus $ 600m from the strategic collaboration with BioNTech and public equity raise in February 2024) – enough to fully support the commercialisation of obe-cel in r/r adult ALL, as well as support obe-cel's pipeline expansion towards pivotal data in autoimmunity. Looking ahead, Autolus is set for an eventful year with an FDA decision on obe-cel in r/r adult ALL (PDUFA 16 November), as well as multiple data readouts including initial data from the phase 1 SLE trial by YE24, which we think could position obe-cel to become a pipeline in a product. We reiterate our BUY rating and $11 TP. Autolus is one of our life sciences top picks.

14/03/2024 1 EN

Underlying

Autolus Therapeutics ADS

See profile

US05280R1005 NASDAQ Stock Market United Kingdom

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Jacob Mekhael

Other Reports on these Companies

GlobeNewsWire

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics to Participate in Upcoming Investor Conferences LONDON and GAITHERSBURG, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in two upcoming investor conferences. TD Cowen 46th Annual Health Care ConferenceDate and time: March 3, 2028; 11:10am EST / 4:10pm GMTLocation: Boston, MAPresenter: Chief Executive Officer Dr. Christian Itin A webcast of the presentation will ...

February 24, 2026 February 24, 2026 1 EN

GlobeNewsWire

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON and GAITHERSBURG, Md., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Compensation Committee of the Company's Board of Directors granted stock option awards to purchase an aggregate of 113,650 American Depositary Shares, representing an equal number of ordinary shares, to 22 employees pursuant to the C...

February 4, 2026 February 4, 2026 1 EN

KBC Securities

Autolus Aucatzyl launch success, FY25 preliminary revenue in line with CSS

Yesterday before US market opens, Autolus announced preliminary unaudited 4Q25 and FY25 net product sales of Aucatzyl (obe-cel, CD19 CAR-T), and provided a business update. $ 75m in FY25 Aucatzyl sales is in line with CSS ($ 75.9m) and ahead of our estimate of $ 72.5m. We believe this figure makes Aucatzyl's first year on the market a success, and we view FY26 guidance of $ 120-135m as within reach. Pipeline wise, we look forward to initial data from the phase 1 trial of Aucatzyl in the difficult progressive MS indication by YE26, while the pivotal nephritis trial is enrolling with a 24 month ...

January 13, 2026 January 13, 2026 1 EN

Sequana Medical Reports 5 centres with alfapump implants since launch

Sequana announces progress in the commercial uptake of the alfapump. We estimate at least 8 implants across 5 hospitals since launch in 2H25. The soft-launch target was 70 implants by end of 1Q26. However, we view this target as challenging to reach. We therefore await FY25 results for greater visibility on definitive sales figures and launch metrics. We reiterate our BUY and € 2.7 TP.

13h / 19m 13h / 19m 1 EN

Kristof Samoy

Kristof Samoy

Aalberts Good results & WC mgmt, higher DPS but lower SBB, no quantified outlook

FY25 release was a mixed bag. Over FY25 Aalberts' topline came in above our expectations organically declining by only -2.5% vs. our -3.8% expectation. Topline stood at €3091m compared to our €3064mE and consensus of €3073mE. Adjusted EBITA of €410m was in line with our €405mE and CSS of €403mE. Overall EBITA margin was in line with earlier guidance at 13.3% (vs. 13.1% CSS, 13.2% KBC). The FCF & NWC management was solid. Declared DPS of €1.15 exceeded expectations but the announced SBB of €75m comes in a tad below our €90m expectations. The issued outlook for ‘unquantified' improvements in org...

13h / 40m 13h / 40m 1 EN

Wim Hoste

Wim Hoste

Corbion FIRST LOOK: FY25 EBITDA +27% organ., FY26 margin guidance of 17%

FY25 adj EBITDA increased by 27% organically and was close to our and consensus forecasts. FY26 guidance of a c. 100bps adj EBITDA margin improvement to around 17% is no surprise (KBCS 16.7%, CSS 16.9%). We remind that Corbion is conducting a strategic review on PLA which we believe will most likely result in an exit of Corbion, while still remaining the lactic acid supplier to the buyer. Biochemicals will be de-emphasized, which will put the growth focus on food preservation and formulation, algal oils and Biomedical Polymers/Pharma. We continue to appreciate Corbion for its market leadership...

13h / 46m 13h / 46m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Autolus FIRST LOOK: Uneventful FY23 results, obe-cel's PDUFA in r/r ALL in 4Q24

We are a financial services provider for several types of professional clients, each with distinct needs.

Autolus Therapeutics to Participate in Upcoming Investor Conferences

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Aucatzyl launch success, FY25 preliminary revenue in line with CSS

Sequana Medical Reports 5 centres with alfapump implants since launch

Aalberts Good results & WC mgmt, higher DPS but lower SBB, no quantified outlook

Corbion FIRST LOOK: FY25 EBITDA +27% organ., FY26 margin guidance of 17%

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe